First published · Last updated
Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors
Journal article reporting post-marketing surveillance of the safety and effectiveness of emicizumab in Japanese patients with congenital haemophilia A with inhibitors. The supplied source data included only the publisher and content type and did not include study details or results.
Categories: public-health
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 3/10
- Geographic reach
- 4/10
- Global importance
- 3/10
- Impact magnitude
- 3/10
- Positivity
- 5/10
- Urgency
- 1/10
Why it matters
This surveillance evaluates a treatment's safety and effectiveness for a defined patient population in Japan.

